FDA inspection
Aurobindo Pharma USA Inc: FDA inspection ending May 15, 2024
FDA inspection 1238442 · Official Action Indicated (OAI) · East Windsor, NJ
Key facts
| Inspection ID | 1238442 |
|---|---|
| Firm | Aurobindo Pharma USA Inc |
| FEI number | 3008460374 |
| Address | 279 Princeton Hightstown Rd |
| City | East Windsor |
| State | NJ |
| ZIP | 08520 |
| Country | United States |
| Fiscal year | 2024 |
| Inspection end date | May 15, 2024 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data